Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria
NCT ID: NCT05780840
Last Updated: 2023-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
6 participants
INTERVENTIONAL
2023-02-23
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
NCT00004940
Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria
NCT00206869
Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria
NCT03682731
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
NCT02426905
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
NCT00004831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dihydroxyacetone
Dihydroxyacetone
Application of 10% dihydroxyacetone (2 mg per square cm skin)
Placebo
Application of lotion to the skin (2 mg per square cm skin)
Placebo
Dihydroxyacetone
Application of 10% dihydroxyacetone (2 mg per square cm skin)
Placebo
Application of lotion to the skin (2 mg per square cm skin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dihydroxyacetone
Application of 10% dihydroxyacetone (2 mg per square cm skin)
Placebo
Application of lotion to the skin (2 mg per square cm skin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Obtainment of written informed consent
Exclusion Criteria
* Use of dihydroxyacetone at the treatment or placebo fields within the last two week
* Sun exposure of the treatment or placebo fields within the last two week
* Use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days)
* Allergy to adhesive bandages, dihydroxyacetone or lotion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ida M. Heerfordt
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ida Marie Heerfordt
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Study protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dihydroxyacetone
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.